d The E-cadherin-GFP mouse allows in situ quantification of Ecadherin mobility In Brief
In Brief Erami et al. generate an E-cadherin-GFP mouse to demonstrate real-time quantification of E-cadherin mobility using intravital photobleaching in a range of tissue types. They show that changes in E-cadherin mobility correlate with changes in cell junction integrity and invasiveness while demonstrating applications of the mouse for future drug discovery studies.
INTRODUCTION
The capacity of cancer cells to dissociate from primary tumors and invade requires the deregulation of interactions with adjacent cells and the surrounding tissue. A major challenge in biology is the real-time monitoring of protein dynamics involved in this process in their native context . The ability to quantify the intricate spatiotemporal regulation of cell adhesion molecules, such as E-cadherin, using techniques including fluorescence recovery after photobleaching (FRAP) has rapidly enhanced our understanding of E-cadherin's subcellular roles in regulating cell-cell integrity and dissociation in vitro (Canel et al., 2010a; Shen et al., 2008; Sprague and McNally, 2005; Wu et al., 2014) .
FRAP is commonly used for monitoring molecular movement within cells. A small fluorescent region is bleached, and fluorescence recovery into the bleached region is measured over time (Axelrod et al., 1976; Fritzsche and Charras, 2015; Sprague and McNally, 2005) . From this, multiple readouts can be derived, including, but not limited to the half-time of recovery, a measure of the rate at which fluorescent molecules move in or out of the region of interest, and the immobile fraction, an indication of how much of the molecule remains trapped and unable to move out of the analyzed region (for in-depth insights into FRAP analysis, see Fritzsche and Charras, 2015) . In the case of fluorescently labeled E-cadherin, the immobile fraction can indicate how much E-cadherin is trapped or engaged in cellcell junctions and may provide a molecular readout of junction stability in real time (Canel et al., 2010b; Serrels et al., 2009) .
FRAP has largely been used to probe molecular events within 2D cell culture using transfection-based approaches (Lippincott-Schwartz et al., 2001; Shen et al., 2008) , whereas its utility in vivo has been limited (Ellenbroek and van Rheenen, 2014) . Recently, we and others have used FRAP in more complex and physiologically relevant environments ranging from application in Drosophila (Cavey et al., 2008) to the use of E-cadherin-GFP FRAP in a mammalian system in vivo (Serrels et al., 2009) , where E-cadherin-GFP-expressing squamous cell carcinoma cells were transplanted and grown subcutaneously in mice. Using this approach, we demonstrated that locally invading cells had a significantly lower immobile fraction of E-cadherin-GFP compared with non-invading cells, illustrating that, in cancer cells that retain E-cadherin expression, mobilization rather than loss of E-cadherin can play a role in reducing cell-cell adhesions, leading to more malleable, motile, and invasive tumor behavior (Friedl et al., 2012; Lamouille et al., 2014; Shamir et al., 2014) . Although these approaches provide insights into the mobilization of E-cadherin in subcutaneous xenograft tumors, they lack the fidelity to recapitulate the complex and distinct microenvironment found in specific organs of interest . It is therefore essential to develop new tools for the quantification of molecular dynamics in distinct organs in which the disease of interest originates, allowing us to understand cell behavior at a subcellular and tissue-and disease-specific level.
In this study, we generated a Cre-inducible E-cadherin-GFP mouse and exploited this model using intravital FRAP imaging to assess changes in E-cadherin-based cell-cell junction integrity during disease progression and in response to drug treatment. Here we mimic the disease etiology of pancreatic cancer in situ, from acquisition of an initiating Kras mutation that occurs in 95% of pancreatic cancers (Biankin et al., 2012; Hingorani et al., 2003) to subsequent loss-or gain-of-function mutations in the tumor suppressor p53, which occur in 50%-75% of pancreatic cancers (Biankin et al., 2012) . Using FRAP analysis, we reveal that E-cadherin stability in normal pancreas or in non-invasive pancreatic tumors (Kras G12D alone or Kras
G12D
; p53 À/À ) remains unaltered during disease progression. However, in mice with Kras G12D and gain-of-function mutations in p53 (p53 R172H ), E-cadherin is mobilized, facilitating the weakening of cell-cell contacts, correlating with the enhanced metastasis seen in this model (Hingorani et al., 2005; Morton et al., 2010b) . Moreover, in line with recent work assessing Src kinase as an anti-invasive drug target (Avizienyte et al., 2002; Morton et al., 2010a; Nobis et al., 2013 Nobis et al., , 2014 , we demonstrate that the phase II drug dasatinib reverts E-cadherin mobilization in invasive pancreatic tumors and that this stabilization of junctions could partially explain its current anti-invasive role in this disease (T.J. Evans et al., 2012, ASCO, abstract) . We therefore present the application of FRAP in the E-cadherin-GFP mouse for live, tissue-specific assessment of vital cell-cell adhesion changes in conjunction with its utility as a pre-clinical imaging tool for evaluating the efficacy of new therapeutics in the pancreas and other organs of interest in real time.
RESULTS
Generation of E-cadherin-GFP Mice for In Vivo FRAP Assessment Conditional E-cadherin-GFP-expressing mice were generated by targeting a lox-stop-lox transgene under the control of a CAG promoter into the deleted Hprt locus of HM1 embryonic stem (ES) cells ( Figure 1A ; Bronson et al., 1996) . We first generated E-cadherin-GFP ''OFF'' mice, a strain in which expression of the extensively validated EGFP-linked E-cadherin fusion protein (Lock and Stow, 2005) was conditionally prevented by a transcriptional stop sequence ( Figure 1A ). To demonstrate the utility and scope of the E-cadherin-GFP mouse for examining the regulation of E-cadherin in different organs, we crossed E-cadherin-GFP OFF mice to tissue-specific Cre strains to induce organ-and cell-type-specific expression in the pancreas (the focus of this study), liver, mammary gland, and pancreatic islets ( Figure 1B ). Expression of E-cadherin-GFP in the pancreas via Pdx1-Cre could be imaged readily at depth (Movie S1, first panel; green, E-cadherin-GFP; purple, second harmonic generation [SHG] imaging of the extracellular matrix [ECM] ). In the liver, E-cadherin-GFP OFF mice were crossed to Cyp1a1-Cre mice (Ireland et al., 2004) , and deletion of the stop cassette was achieved after three doses of 2 mg b-naphthoflavone over 8 hr (Movie S1, second panel). Robust expression in mammary tissue via MMTV-Cre (Wagner et al., 1997) was imaged in the alveoli of lactating mice where junction integrity is required during milk production (Movie S1, third panel; Figures S1A and S1B), whereas sub-organ specificity within islet cells of the pancreas via RIP-Cre (Postic et al., 1999) could be demonstrated in isolated pancreatic islets (Movie S1, fourth panel). Conditional E-cadherin-GFP mice were subsequently crossed to mice expressing CMV Cre recombinase (Schwenk et al., 1995) to enable constitutive, low-level expression of E-cadherin-GFP in every tissue ( Figure 1C ). Analysis of E-cadherin in multiple tissue types from the E-cadherin-GFP ''ON'' mouse illustrates the broader capacity for subcellular FRAP imaging in normal or disease contexts of interest ( Figure 1D ; Movie S2, left panels, kidney, brain and salivary gland; right panels, pancreas, liver, and mammary tissue). Importantly, mice of both E-cadherin-GFP strains were born at the expected Mendelian ratio, were fertile and healthy, and exhibited no untoward behaviors. In this study, we demonstrate the application of photobleaching in the E-cadherin-GFP mouse as a method for assessing the subcellular regulation of E-cadherin in the progression of invasive pancreatic cancer. However, this system could be used in other disease states in future investigations. Figure 2A ; Movie S3) serve as a fluorescent model system to gauge the initial spatiotemporal regulation of E-cadherin in pancreatic cancer (Morton et al., 2010b; Muller et al., 2013; Tan et al., 2014) without affecting fundamental processes such as cell proliferation or invasive capacity (Figures S1C and S1D). FRAP recovery curves from time-lapse movies of p53 À/À vector or p53 À/À R175H primary PDAC cells were then analyzed (Canel et al., 2010a (Canel et al., , 2010b Serrels et al., 2009; Vlahov et al., 2015 ; Supplemental Experimental Procedures; Figure S2 ). Assessment in two dimensions revealed no difference in E-cadherin mobility of invasive p53 À/À R175H versus non-invasive p53 À/À vector cells ( Figure 2B , blue recovery curve versus green), where the fraction of E-cadherin-GFP stabilized in cellcell junctions was similar in both cell types ( Figure 2C , mobile fraction 45.6% ± 2.7% for p53 À/À vector compared with 46% ± 3.1% for p53 À/À R175H cells).
Critically, assessment in a 3D environment using cells grown on cell-derived matrices (CDMs) to mimic in vivo conditions Yamada and Cukierman, 2007) Figure S3A ). This is in line with the early cell-cell dissociation preceding cell scattering and invasion we observed recently in mutant p53 cells compared with p53 À/À cells (Muller et al., 2013; Tan et al., 2014) and highlights the need to assess E-cadherin cell-cell adhesion events in a 3D context. arrows). These zones persisted over the time course of imaging and could represent stable E-cadherin zones, as identified previously by others (Adams et al., 1998; Cavey et al., 2008) . To quantify the uniformity or texture of this E-cadherin intensity across the membrane, we used orientation-dependent grey level cooccurrence matrix (OD-GLCM) analysis of the kymographs ( Figure S3B ; Hu et al., 2012; Nobis et al., 2013) . This analysis revealed that the inherent distribution of high-intensity E-cadherin-GFP zones was significantly different between p53 À/À vector and p53 À/À R175H junctions (quantified as contrast in Fig Columns, mean; bars, ± SE. *p < 0.05; **p < 0.01; ***p < 0. 32.1% ± 2.9% versus 18.8% ± 1.7%; Figure S3F ; Movie S5 To further investigate the differences in E-cadherin mobility between p53 À/À vector and p53 À/À R175H tumors, we bleached a large region of interest with a 3-mm diameter. The change in intensity profile along the membrane of a large FRAP bleach region over time can provide insights into the processes governing recovery (modeled in Figures 4A and 4B ). We therefore generated kymographs of the bleached junction and measured the fluorescence intensity along the junction via line scan analysis at defined time points (Figures 4C and 4F, colored arrowheads; de Beco et al., 2012; Delva and Kowalczyk, 2009 ). We then fitted the results of our line scan analysis to a Gaussian curve model ( Figures 4D and 4G ) and plotted the decrease in width of the Gaussian curves over time as a measure of the speed of fluorescence recovery (Figures 4E and 4H) . If the recovery was due to lateral movement in the membrane, then the width of the bleached region should increase linearly with time ( Figure 4A ). Conversely, if the recovery was due to cytoplasmic uniformed exchange, then the width of the bleached region should remain uniform with time ( Figure 4B ). Here we find that the width of the bleached region expands significantly faster in p53 the increase in E-cadherin mobility observed in locally invasive p53 À/À R175H xenografts may be primarily attributed to increased mobility within the membrane. Although this subcutaneous model confirmed that enhanced mobilization of E-cadherin exists in live 3D tumor settings, it does not recapitulate the distinct microenvironment found in the pancreas. This prompted us to investigate whether subcellular mobilization of E-cadherin occurs in the organ of tumor origin and, if so, whether the stage of in situ disease progression in which these changes occur can be identified (Bardeesy and DePinho, 2002) .
FRAP in the E-cadherin-GFP Mouse Reveals Genetically Driven Progression of Cell-Cell Junction Disruption in Pancreatic Tissue during In Situ Disease Development Our ability to use FRAP in vivo led us to investigate whether we can assess E-cadherin mobility in live pancreatic tissue. The E-cadherin-GFP mouse was therefore crossed with either wildtype mice expressing Pdx1-Cre, mice bearing a Pdx1-Credriven initiating Kras G12D mutation alone, Pdx1-Cre; Kras G12D ; p53 À/À mice, or Pdx1-Cre; Kras G12D ; mutant p53 R172H mice and monitored for $150 days to allow tumor formation to occur. This allowed us to recapitulate the genetic changes commonly occurring during the formation of invasive PDAC (Figures 5A-5C; Movie S7) in this extensively validated model of pancreatic cancer.
FRAP recovery curves from time-lapse movies of wild-type E-cadherin-GFP mice ( Figure 5D , green line) were analyzed to gauge the inherent mobility of E-cadherin in normal pancreatic tissue ( Figure 5E , average mobile fraction = 21.9% ± 1.6%; Figure S4A) . Interestingly, the fraction of E-cadherin stabilized in cell-cell junctions in wild-type mice was similar to that of noninvasive tumors bearing Kras G12D ( Figures 5D and 5E , blue line, mobile fraction = 24.3% ± 2.3%). This indicates that initiating Kras G12D mutations in the pancreas are not sufficient to drive E-cadherin mobilization in situ. Importantly, loss of p53 on a Kras G12D background from agematched tumors also had no effect on E-cadherin mobility compared with normal pancreatic tissue or Kras G12D tumors alone ( Figures 5D and 5E , purple line, 21.6% ± 1.7% mobile fraction). This demonstrates that, although loss of the tumor suppressor p53 in combination with initiating Kras G12D mutations enhances tumor progression, it does not act to mobilize E-cadherin, correlating with the lack of invasion or metastasis we observed previously in Kras
G12D
; p53 À/À mice (Morton et al., 2010b) . Critically, FRAP analysis of tumors from $150-day-old, Kras G12D ; p53
R172H ; E-cadherin-GFP mice revealed that gainof-function mutations in p53 on a Kras G12D background significantly mobilizes E-cadherin junctions in the pancreas ( Figures  5D and 5E , orange line, 31.8% ± 1.8% mobile fraction compared with the average of 22.4% ± 1.1% found in normal pancreas, , or Kras G12D ; p53 À/À tumors). This indicates that acquisition of mutant p53 R172H , which we have shown previously to drive an invasive and metastatic program over and above the loss of p53 in pancreatic cancer (Morton et al., 2010b) , could partially achieve this by allowing early tumor dissolution via mobilization of E-cadherin-based cell-cell contacts ( Figure 5F ). Therefore, we sought to assess whether this potentially pro-invasive molecular event could be impaired pharmacologically and monitored in a pre-clinical setting using the E-cadherin-GFP mouse.
The E-cadherin-GFP Mouse as a Tool to Monitor Early Anti-invasive Drug Response in Real Time
Recently we demonstrated that Src kinase, which is known to induce the disruption of E-cadherin-based cell-cell junctions either directly (Avizienyte et al., 2002; Calautti et al., 1998; Frame et al., 2002) or indirectly via the stroma (Yang et al., 2010) , plays a prominent role in invasive pancreatic cancer (Morton et al., 2010a) . We therefore examined whether the mobilization and potential weakening of E-cadherin junctions observed in invasive pancreatic tumors of Pdx1-Cre; Kras
G12D
; p53 R172H E-cadherin-GFP mice could be reverted using dasatinib.
As before, Pdx1-Cre; Kras   G12D ; p53 R172H ; E-cadherin-GFP mice were allowed to form tumors for $150 days and, upon signs of tumor burden, were placed on daily dasatinib treatment (10 mg/kg) for 3 consecutive days ( Figure 6A ), followed by FRAP analysis ( Figure 6B ; Movie S7). This revealed that reversion of E-cadherin mobilization back to the levels found in wild-type pancreas or non-invasive Kras G12D ; p53 À/À tumors could be achieved using dasatinib treatment at this stage of the disease ( Figures 6C and 6D , compare mobile fraction of Kras
; p53 R172H mice ± dasatinib, 18.1% ± 1.3% versus 31.8% ± 1.8%, and 5E, Kras G12D alone or Kras
; p53
, mobile fraction of 24.3% ± 2.3% and 21.6% ± 1.7%; Figure S4B) . These results indicate that the recently demonstrated efficacy of dasatinib in this model could partly be due to its capacity to stabilize E-cadherin junctions and prevent dissociation from the primary tumor. We therefore sought to determine whether the E-cadherin-GFP FRAP readouts we observed in this study could be correlated with changes in junction integrity and strength. (B) Representative whole-body image of an E-cadherin-GFP mouse with multiphoton-based cell-cell junction imaging (inset: E-cadherin-GFP, green; SHG signal, purple). (C) Representative images from confocal FRAP movies in the E-cadherin-GFP mouse from normal pancreas (first row) to acquiring Kras G12D (second row) with subsequent loss of p53 (third row) or p53 R172H gain-of function mutations (bottom row), respectively. Red arrows, bleached regions.
(D and E) Graphs comparing E-cadherin-GFP mobilization between in situ pancreatic tissue from normal (green), Kras G12D alone (blue), Kras
; p53 À/À (purple), and Kras
; p53 R172H (orange) mice. Columns, mean; bars, ± SE, n = 3 mice/group, R21 junctions in total. *p < 0.05 (unpaired Student's t test).
(F) Proposed schematic of E-cadherin dynamics during PDAC progression. See also Figure S4 . R172H ; E-cadherin-GFP mice. Columns, mean; bars, ± SE; n = 3 mice/group, R21 junctions in total. **p < 0.
(unpaired Student's t test). (E and F) TEER (E) and Dispase assays (F) in E-cadherin-GFP-transfected p53
À/À PDAC cells (columns 1 and 3, pre-dasatinib; columns 5 and 7, post-dasatinib) versus mutant p53 PDAC cells (columns 2 and 4, pre-dasatinib; columns 6 and 8, post-dasatinib). Columns, mean; bars, ± SE; n = 3 mice/group. *p < 0.05; **p < 0.01 (unpaired Student's t test). See also Figure S4 .
Using complementary assays, we interrogated the integrity and strength of cell-cell junctions using trans-endothelial electrical resistance (TEER) and Dispase II assays, respectively (Calautti et al., 1998; Canel et al., 2010b; von Bonsdorff et al., 1985) . TEER allows a rapid evaluation of junction integrity as a function of electrical resistance between cells where high resistance correlates with high junction integrity (von Bonsdorff et al., 1985) . Examination of the electrical resistance between non-invasive p53 À/À and invasive p53 R172H cells
transfected with E-cadherin-GFP demonstrated that junction integrity was significantly lower in a mutant p53 R172H background than in a p53 À/À setting ( Figure 6E , columns 1 and 2).
Similar results were obtained in E-cadherin-GFP-transfected p53 À/À R175H and p53 À/À vector cells ( Figure 6E , columns 3 and 4), confirming that mutant p53 reduces junction integrity in PDAC cells.
In line with our results demonstrating that dasatinib impairs invasion via potentially enhancing cell-cell adhesions, TEER analysis of dasatinib-treated mutant p53-expressing PDAC cells (E-cadherin-GFP-transfected p53 R172H or p53 À/À R175H cells)
revealed that Src inhibition ( Figures S4D and S4E ) stabilized and strengthened junctions to a similar level as that found in a non-invasive p53 À/À setting ( Figure 6E , columns 5-8). This was confirmed using the Dispase II assay, where mutant p53 cells (E-cadherin-GFP-transfected p53 R172H or p53
show an increased number of single cells upon mechanical disruption compared with p53 À/À E-cadherin-GFP-transfected counterparts ( Figure 6F , columns 1-4). Importantly, cell dissociation was reverted to similar levels as those found in non-invasive p53 À/À or vector-alone counterparts when mutant p53 cells were treated with dasatinib ( Figure 6F , compare columns 1-4 with columns 5-8). These results illustrate that mutant p53 on an initiating Kras G12D background weakens cell-cell junction strength, which could lead to tumor dissociation, and that Src inhibition can partially impair this breakdown. Importantly, we corroborated these finding with another Src inhibitor, saracatenib (Figures S4D and S4E ; Nam et al., 2013) , and observed a similar strengthening and enhancement of junction integrity via TEER and Dispase II analysis ( Figures S4F and S4G) , with a corresponding stabilization of E-cadherin mobility, as assessed by FRAP on CDMs ( Figure S4C ). These data, therefore, demonstrate that imaging subtle changes in the mobility of proteins involved in maintaining normal epithelial architecture, such as E-cadherin, can provide a surrogate marker of dissociation events that may precede the collapse of cell-cell adhesions, correlating with tumor cell invasion.
Monitoring E-cadherin Dynamics in Secondary Metastases
In line with the concept of stabilizing E-cadherin junctions via Src inhibition, we isolated metastatic tumor cells that had colonized the liver of invasive Pdx1-Cre; Kras G12D ; p53 R172H ; E-cadherin-GFP mice using whole-body fluorescence imaging ( Figures 7A  and 7B , whole-body imaging and inset, respectively, showing primary tumor and liver micro-metastases isolated from the same mouse). We confirmed that metastatic cells from the E-cadherin-GFP mouse retained similar E-cadherin expression levels as cell lines obtained from primary tumors, and similar levels of proliferation ( Figures 7C-7E, Figures S5A and S5B) , while maintaining the capacity to invade in 3D organotypic matrices ( Figures 7F, 7G, and S5C, left) . Importantly, upon treatment of these invasive cells with dasatinib, invasion was reduced significantly compared with control cells (Figures 7F, 7G , and S5C, right, for three independent metastatic lines from three independent mice [101912 met, 101025 met, and 111375 met, respectively]). Moreover, the integrity of cell-cell contacts in all lines was partially restored under dasatinib-treated conditions, leading to enhanced cell-cell clustering ( Figures 7F, 7G , and S5C). Subcellular immunofluorescent staining of E-cadherin showed improved cell clustering in cells treated with dasatinib ( Figures 7H, 7I, and S5D, red arrows) . Importantly, we observed a similar reduction in invasion and a restoration in junction integrity for all three metastatic cell lines treated with saracatenib in organotypic assays ( Figure S6A-S6E) . Collectively, these data indicate that Src inhibition may partially stabilize E-cadherinbased cell-cell junctions and could retard early pancreatic tumor cell dissociation and, subsequently, decrease invasive efficiency by inducing tumor cell clustering.
This led us to examine whether the enhanced mobilization of E-cadherin and weakening of junction strength observed in invasive mutant p53 pancreatic tumors (Figures 3 and 5) could also be partly reverted in these more aggressive metastatic lines from the E-cadherin-GFP mouse. As before, TEER and Dispase II assays were carried out, and, in all three metastatic lines, a significant enhancement in junction integrity and strength was observed following dasatinib treatment ( Figures  7J, 7K , and S5E). Again, similar effects on TEER and Dispase II analysis were observed upon saracatenib treatment in all three metastatic cell lines (Figures S6F-S6H ). In contrast, dasatinib and saracatenib treatment had no effect on junction integrity and strength in primary tumor cells isolated from Pdx1-Cre; Kras G12D ; p53 À/À ; E-cadherin-GFP mice ( Figures S5F and S6I ), which inherently possess high junction strength and integrity. Lastly, in line with our CDM and xenograft data (Figures 2  and 3) , OD-GLCM analysis of mutant metastatic lines also revealed a reduction in contrast and a more uniform, malleable organization of E-cadherin-GFP distribution compared with primary tumor cells isolated from Pdx1-Cre; Kras
G12D
À/À ; E-cadherin-GFP mice ( Figures S6J and S6K) , suggesting that E-cadherin destabilization is maintained in mutant p53 metastatic cells derived from the E-cadherin-GFP mouse. Collectively, these results highlight the utility of the E-cadherin-GFP mouse as a pre-clinical imaging tool for monitoring early subcellular molecular changes that correlate with more aggressive tumor behavior.
DISCUSSION
Downregulation or loss of E-cadherin expression occurs in a number of cancer types and is thought to play a key role in epithelial-to-mesenchymal transition (EMT) associated with invasive cancer phenotypes (Gregory et al., 2008; Lamouille et al., 2014) . However, in many invasive cancers, including pancreatic cancer, E-cadherin expression is often retained (David and Rajasekaran, 2012; Shamir et al., 2014) 2015; Wicki et al., 2006) . This indicates that, in many cases, deregulation of E-cadherin mobility rather than expression level may play an additional role in promoting invasion and suggests that monitoring E-cadherin behavior in this context could lead to a greater understanding of cancer invasion and response to new therapeutics (Wicki et al., 2006) . Here, we present the generation of an E-cadherin-GFP mouse in which E-cadherin behavior can be monitored within intact tissues, such as the pancreas, liver, brain, kidney, and mammary tissue, via FRAP. Using this mouse in the context of pancreatic cancer, we reveal significant biological insights into the in situ regulation of E-cadherin during normal tissue homeostasis, disease initiation, and progression of pancreatic cancer while highlighting its potential utility for monitoring drug target activity in vivo using FRAP. We chose the Hprt locus to drive E-Cadherin-GFP expression to provide the best signal-to-noise ratio for intravital imaging while aiming to minimize disturbance to early developmental events, such as tissue sorting (Halbleib and Nelson, 2006) , and normal tissue function. Our assessment of the E-cadherin-GFP mouse, in the context of the comprehensively characterized Kras G12D/+ ; Trp53 R172H/+ ; Pdx1-Cre (KPC) mouse model of pancreatic cancer, suggests that we gauged expression levels well, providing enough fluorescence for detection of pre-and post-photobleaching events without affecting primary tumor growth and metastasis. This is in line with our recent development of the Rac-Fö rster resonance energy transfer (FRET) biosensor mouse in which low-level expression driven via the ROSA26 locus provided a sufficient signal for in vivo FRET imaging during disease progression without affecting the biology of the cells (Johnsson et al., 2014) .
Crossing the E-cadherin-GFP mouse with distinct genetic models of pancreatic cancer has demonstrated its utility for examining the effects of specific mutations on E-cadherin in a time-and tissue-specific and subcellular manner. In pancreatic cancer, initiating mutations in the KRAS gene occur in approximately 95% of patients and are often followed by sequential accumulation of genetic alterations, such as loss of expression, function, or mutations in tumor suppressors and regulators, such as TP53, CDKN2A, INK4A/ARF, and/or PTEN (Bardeesy and DePinho, 2002; Kennedy et al., 2011; Ling et al., 2012; Morran et al., 2014) . Although we know the frequency of such mutations in PDAC (Biankin et al., 2012) , their specific function during development of invasive pancreatic cancer remains unclear. Here, we show that acquiring Kras G12D mutations or subsequent loss of p53 on a Kras G12D background in the pancreas is not sufficient to drive alterations to E-cadherin mobility, whereas acquisition of a gain-of-function mutation in p53 on the same initiating Kras G12D background mobilizes E-cadherin, consistent with the tumor dissolution and metastasis found in these mice. Importantly, reduction or reversion of cell-cell junction strength was achieved by molecular manipulation in the form of overexpressing the human equivalent of murine p53 R172H (R175H) or inhibiting E-cadherin mobilization via Src inactivation, respectively. This demonstrates that mutant p53 can partially drive the breakdown of tumors by disrupting E-cadherin cellcell engagement via Src. It should be noted that both dasatinib and saracatenib, while inhibiting Src kinase, also target Abl and other kinases (Haubeiss et al., 2010) and were used here in a proof-of-principle context to demonstrate the utility of the mouse in pre-clinical drug discovery applications. To this end, the E-cadherin-GFP mouse could also be used to decipher other molecular pathways downstream of mutant p53 to be targeted in future studies or be used with other Kras or p53 mutations to determine whether E-cadherin mobilization is a general phenomenon for all mutant p53 variants in this disease (Muller et al., 2009 (Muller et al., , 2013 Muller and Vousden, 2014) .
It is important to note that, in this study, we examined E-cadherin-GFP mobility throughout the entire pancreatic tumor tissue. However, heterogeneity is a hallmark of in vivo cancer, and it will be possible, in the future, to map areas of weakened cell-cell adhesions or drug response in the KPC model by examining E-cadherin mobilization in the center versus the invasive front of the tumor (Serrels et al., 2009) . Similarly, the drug response in cancer cells in relation to local blood or drug supply could be assessed, as we and others have described previously (Manning et al., 2013; Nobis et al., 2013) . In this way, we could determine, in the future, whether spatially regulated environmental cues in the native pancreas drive this heterogeneity or reflect a gradient in anti-invasive drug response in vivo.
Finally, the intricate control of in vivo distribution, function, as well as potential redundancy of EMT regulators such as Snail, Slug, Zeb, or Twist (Brabletz et al., 2013) could be investigated in pancreatic or other cancer types using the E-cadherin-GFP mouse. This could help dissect, in real time, the complex changes in E-cadherin mobility that occur during EMT, which, in many cases, does not involve loss of E-cadherin expression but rather a more complex dynamic regulation and utilization of E-cadherin function (David and Rajasekaran, 2012; Shamir et al., 2014; Wu et al., 2015) .
The location, signaling, and dynamics of E-cadherin in the context of the surrounding environment can play a vital role in disease progression. Our capacity to isolate and image micrometastases in the liver illustrates the power of this model for assessing subcellular changes in E-cadherin dynamics at secondary tumor sites that retain E-cadherin expression and may take advantage of this existing pool of E-cadherin during the early stages of mesenchymal-to-epithelial transition (MET) and tumor colonization (Lamouille et al., 2014; Ocañ a et al., 2012) . EMT-to-MET switching during extravasation and colonization is thought to be controlled precisely and has significant implications on whether anti-invasive drug targeting will be effective in impairing subsequent tumor colonization of the primary tumor in secondary sites (Brabletz et al., 2013) . Preventing niche localization at the early stage of colonization by using anti-migratory drug targeting has been shown recently to be an effective strategy in impairing metastasis formation in the liver (Ritsma et al., 2012) . However, understanding when and where EMT versus MET are detrimental or conducive to tumor extravasation will be of great interest in the future (Brabletz et al., 2013) . Therefore, FRAP in the E-cadherin-GFP mouse could help us to understand this largely unexplored area of the metastatic cascade in a spatiotemporal and pre-clinical manner by allowing us to follow E-cadherin dynamics in both primary and secondary sites in the same mouse.
We focus on the application of FRAP in this study. However, other imaging techniques such as FLIP or anisotropy imaging of homo-FRET could also be employed in the future using the E-cadherin-GFP mouse to address more fundamental questions regarding E-cadherin regulation at distinct points in the membrane in situ (Levitt et al., 2015; Roberti et al., 2011) . Furthermore, for fine-tuned assessment of E-cadherin via the endogenous E-cadherin promoter, engineering of a knockin E-cadherin-GFP mouse is currently underway as a next-generation mouse. Therefore, subtle changes to both E-cadherin levels and mobility could be monitored simultaneously during disease progression in cancers that also modulate E-cadherin expression. This could avoid any potential caveats or off-target effects caused by wrong lineage expression and could circumvent any minor changes to physiology that may have gone undetected in our model. Endogenous knockin strategies have been employed recently to examine the intricate dynamics of other cell-cell junction types in situ via the recent generation of ZO-1-GFP mice (Foote et al., 2013) . Here, in line with our current work on adherens junctions, the authors report fundamental differences in tight junction dynamics in epidermal tissue in vivo, which cannot be recapitulated using 2D culture as a surrogate for living tissue. However, others have shown that E-cadherin can be differentially regulated within distinct points on the membrane, which could potentially be associated with zona adherens crosstalk (Priya et al., 2013) .
In conclusion, FRAP in the E-cadherin-GFP mouse provides a flexible approach to monitor the intricate control of E-cadherin junctions in distinct biological processes in a time-, location-, and signaling-specific context. Future applications of this mouse as a tool alone or in combination with deficiencies of E-cadherin regulators and other tight junction components will profoundly expand our insights into the networks that govern E-cadherin responses in developmental, normal, or disease states while guiding therapeutic intervention strategies aimed at targeting cell-cell junctions during disease progression.
EXPERIMENTAL PROCEDURES
Generation of E-cadherin-GFP Mice A cDNA encoding EGFP-linked E-cadherin fusion protein (Lock and Stow, 2005) was cloned into pHPRT.CAAG.STOP downstream of a lox-stop-lox cassette, and the transgene was recombineered into pSKB1 (Bronson et al., 1996) to generate the final targeting vector. Upon germline transmission, the lox-stop-lox-E-cadherin-GFP mice (OFF mice) were bred with tissue-specific Cre driver lines or with CMV-Cre ''deleter'' mice to generate E-cadherin-GFP ON mice with ubiquitous E-cadherin-GFP expression.
All Confocal Photobleaching Experiments in Cell Culture, Cell-Derived Matrix and In Vivo Confluent cells were imaged on 35-mm glass bottom dishes at 37 C and 5%
CO 2 using a Leica DMI 6000 SP8 confocal microscope or an Olympus FV1000 confocal microscope with a SIM scanner (Serrels et al., 2009 ). For photobleaching (FRAP, FLIP) experiments in live xenograft tumors, mice were anesthetized using a combination of 1:1 hypnorm -H 2 O + 1:1 hypnovel -H 2 O, and the subcutaneous tumor was exposed surgically via a skin flap procedure (Serrels et al., 2009) 
